Does the media prefer ZBH or MMED?

In the previous week, Zimmer Biomet had 10 more articles in the media than MiniMed Group. MarketBeat recorded 15 mentions for Zimmer Biomet and 5 mentions for MiniMed Group. Zimmer Biomet's average media sentiment score of 0.81 beat MiniMed Group's score of 0.29 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SOLV or MMED?

Solventum has higher revenue and earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.83 $1.56B $8.16 10.79 MiniMed Group $3.10B 1.72 -$190.97M -$0.68 N/A

Does the media favor SOLV or MMED?

In the previous week, Solventum had 4 more articles in the media than MiniMed Group. MarketBeat recorded 9 mentions for Solventum and 5 mentions for MiniMed Group. Solventum's average media sentiment score of 0.72 beat MiniMed Group's score of 0.29 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, SNN or MMED?

Smith & Nephew SNATS has higher revenue and earnings than MiniMed Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.09 $625M N/A N/A MiniMed Group $3.10B 1.72 -$190.97M -$0.68 N/A

Is SNN or MMED more profitable?

Company Net Margins Return on Equity Return on Assets Smith & Nephew SNATS N/A N/A N/A MiniMed Group N/A N/A N/A

Does the media refer more to SNN or MMED?

In the previous week, Smith & Nephew SNATS had 6 more articles in the media than MiniMed Group. MarketBeat recorded 11 mentions for Smith & Nephew SNATS and 5 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 0.29 beat Smith & Nephew SNATS's score of -0.18 indicating that MiniMed Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PEN or MMED?

In the previous week, Penumbra had 3 more articles in the media than MiniMed Group. MarketBeat recorded 8 mentions for Penumbra and 5 mentions for MiniMed Group. Penumbra's average media sentiment score of 0.73 beat MiniMed Group's score of 0.29 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, MMED or GKOS?

Glaukos has lower revenue, but higher earnings than MiniMed Group. Glaukos is trading at a lower price-to-earnings ratio than MiniMed Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiniMed Group $3.10B 1.72 -$190.97M -$0.68 N/A Glaukos $507.44M 19.78 -$187.69M -$3.25 N/A

Does the media favor MMED or GKOS?

In the previous week, Glaukos had 23 more articles in the media than MiniMed Group. MarketBeat recorded 28 mentions for Glaukos and 5 mentions for MiniMed Group. Glaukos' average media sentiment score of 0.74 beat MiniMed Group's score of 0.29 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 10 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

MiniMed Group (MMED) Competitors

$18.99 -0.11 (-0.58%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$19.18 +0.19 (+1.00%)

As of 08:18 AM Eastern

Compare

MMED vs. ZBH, SOLV, SNN, PEN, and GKOS

Should you buy MiniMed Group stock or one of its competitors? MarketBeat compares MiniMed Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiniMed Group include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Glaukos (GKOS).

How does MiniMed Group compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and MiniMed Group (NASDAQ:MMED) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

In the previous week, Zimmer Biomet had 10 more articles in the media than MiniMed Group. MarketBeat recorded 15 mentions for Zimmer Biomet and 5 mentions for MiniMed Group. Zimmer Biomet's average media sentiment score of 0.81 beat MiniMed Group's score of 0.29 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zimmer Biomet has higher revenue and earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.41B	2.21	$705.20M	$3.85	24.94
MiniMed Group	$3.10B	1.72	-$190.97M	-$0.68	N/A

Zimmer Biomet presently has a consensus price target of $102.00, suggesting a potential upside of 6.22%. MiniMed Group has a consensus price target of $21.62, suggesting a potential upside of 13.83%. Given MiniMed Group's stronger consensus rating and higher possible upside, analysts plainly believe MiniMed Group is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	4 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.24
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Zimmer Biomet has a net margin of 9.05% compared to MiniMed Group's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
MiniMed Group	N/A	N/A	N/A

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 19.7% of MiniMed Group shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 2.2% of MiniMed Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Zimmer Biomet beats MiniMed Group on 12 of the 16 factors compared between the two stocks.

How does MiniMed Group compare to Solventum?

Solventum (NYSE:SOLV) and MiniMed Group (NASDAQ:MMED) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Solventum has a net margin of 17.33% compared to MiniMed Group's net margin of 0.00%. Solventum's return on equity of 23.51% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
MiniMed Group	N/A	N/A	N/A

19.7% of MiniMed Group shares are held by institutional investors. 0.2% of Solventum shares are held by company insiders. Comparatively, 2.2% of MiniMed Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Solventum has higher revenue and earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.83	$1.56B	$8.16	10.79
MiniMed Group	$3.10B	1.72	-$190.97M	-$0.68	N/A

In the previous week, Solventum had 4 more articles in the media than MiniMed Group. MarketBeat recorded 9 mentions for Solventum and 5 mentions for MiniMed Group. Solventum's average media sentiment score of 0.72 beat MiniMed Group's score of 0.29 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solventum presently has a consensus price target of $86.00, indicating a potential downside of 2.32%. MiniMed Group has a consensus price target of $21.62, indicating a potential upside of 13.83%. Given MiniMed Group's stronger consensus rating and higher possible upside, analysts clearly believe MiniMed Group is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Solventum beats MiniMed Group on 10 of the 15 factors compared between the two stocks.

How does MiniMed Group compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and MiniMed Group (NASDAQ:MMED) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 19.7% of MiniMed Group shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 2.2% of MiniMed Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
MiniMed Group	N/A	N/A	N/A

Smith & Nephew SNATS currently has a consensus target price of $30.93, suggesting a potential upside of 1.45%. MiniMed Group has a consensus target price of $21.62, suggesting a potential upside of 13.83%. Given MiniMed Group's stronger consensus rating and higher possible upside, analysts plainly believe MiniMed Group is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Smith & Nephew SNATS has higher revenue and earnings than MiniMed Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.09	$625M	N/A	N/A
MiniMed Group	$3.10B	1.72	-$190.97M	-$0.68	N/A

In the previous week, Smith & Nephew SNATS had 6 more articles in the media than MiniMed Group. MarketBeat recorded 11 mentions for Smith & Nephew SNATS and 5 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 0.29 beat Smith & Nephew SNATS's score of -0.18 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Smith & Nephew SNATS and MiniMed Group tied by winning 5 of the 10 factors compared between the two stocks.

How does MiniMed Group compare to Penumbra?

Penumbra (NYSE:PEN) and MiniMed Group (NASDAQ:MMED) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Penumbra currently has a consensus price target of $367.07, indicating a potential upside of 13.24%. MiniMed Group has a consensus price target of $21.62, indicating a potential upside of 13.83%. Given MiniMed Group's stronger consensus rating and higher probable upside, analysts plainly believe MiniMed Group is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Penumbra has a net margin of 10.67% compared to MiniMed Group's net margin of 0.00%. Penumbra's return on equity of 10.50% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
MiniMed Group	N/A	N/A	N/A

Penumbra has higher earnings, but lower revenue than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.10	$177.69M	$4.07	79.64
MiniMed Group	$3.10B	1.72	-$190.97M	-$0.68	N/A

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 19.7% of MiniMed Group shares are owned by institutional investors. 2.9% of Penumbra shares are owned by insiders. Comparatively, 2.2% of MiniMed Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Penumbra had 3 more articles in the media than MiniMed Group. MarketBeat recorded 8 mentions for Penumbra and 5 mentions for MiniMed Group. Penumbra's average media sentiment score of 0.73 beat MiniMed Group's score of 0.29 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Penumbra beats MiniMed Group on 11 of the 15 factors compared between the two stocks.

How does MiniMed Group compare to Glaukos?

MiniMed Group (NASDAQ:MMED) and Glaukos (NYSE:GKOS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

In the previous week, Glaukos had 23 more articles in the media than MiniMed Group. MarketBeat recorded 28 mentions for Glaukos and 5 mentions for MiniMed Group. Glaukos' average media sentiment score of 0.74 beat MiniMed Group's score of 0.29 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	10 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

19.7% of MiniMed Group shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 2.2% of MiniMed Group shares are held by insiders. Comparatively, 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MiniMed Group currently has a consensus target price of $21.62, suggesting a potential upside of 13.83%. Glaukos has a consensus target price of $177.33, suggesting a potential upside of 4.19%. Given MiniMed Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe MiniMed Group is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

MiniMed Group has a net margin of 0.00% compared to Glaukos' net margin of -30.68%. MiniMed Group's return on equity of 0.00% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Glaukos	-30.68%	-6.37%	-4.78%

Glaukos has lower revenue, but higher earnings than MiniMed Group. Glaukos is trading at a lower price-to-earnings ratio than MiniMed Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.10B	1.72	-$190.97M	-$0.68	N/A
Glaukos	$507.44M	19.78	-$187.69M	-$3.25	N/A

Summary

MiniMed Group beats Glaukos on 9 of the 15 factors compared between the two stocks.

Get MiniMed Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MMED vs. The Competition

Export

Metric	MiniMed Group	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.33B	$5.78B	$6.83B	$12.77B
Dividend Yield	N/A	1.78%	2.60%	10.01%
P/E Ratio	-27.93	23.44	279.15	25.53
Price / Sales	1.72	44.13	587.36	92.31
Price / Cash	N/A	32.60	72.11	49.39
Price / Book	N/A	6.13	13.06	6.11
Net Income	-$190.97M	$150.91M	$3.48B	$347.58M
7 Day Performance	3.21%	5.99%	3.38%	4.91%
1 Month Performance	21.81%	1.01%	-2.81%	-2.06%
1 Year Performance	N/A	9.10%	73.07%	21.03%

MiniMed Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MMED MiniMed Group	2.1335 of 5 stars	$18.99 -0.6%	$21.62 +13.8%	N/A	$5.33B	$3.10B	N/A	8,000	Gap Up
ZBH Zimmer Biomet	3.0874 of 5 stars	$91.35 +1.9%	$100.70 +10.2%	+3.8%	$17.67B	$8.23B	23.73	17,000	Positive News Earnings Report Gap Up
SOLV Solventum	2.9931 of 5 stars	$78.02 +1.0%	$81.91 +5.0%	+20.2%	$13.51B	$8.33B	9.56	20,000	Positive News
SNN Smith & Nephew SNATS	1.8287 of 5 stars	$30.53 +2.6%	$30.93 +1.3%	-1.0%	$12.92B	$6.16B	N/A	16,988	News Coverage Analyst Downgrade
PEN Penumbra	2.7561 of 5 stars	$318.60 +0.2%	$360.33 +13.1%	+34.7%	$12.54B	$1.45B	73.41	4,700	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MMED) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiniMed Group (MMED) Competitors

MMED vs. ZBH, SOLV, SNN, PEN, and GKOS

How does MiniMed Group compare to Zimmer Biomet?

Summary

How does MiniMed Group compare to Solventum?

Summary

How does MiniMed Group compare to Smith & Nephew SNATS?

Summary

How does MiniMed Group compare to Penumbra?

Summary

How does MiniMed Group compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MMED vs. The Competition

MiniMed Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiniMed Group (MMED) Competitors

MMED vs. ZBH, SOLV, SNN, PEN, and GKOS

How does MiniMed Group compare to Zimmer Biomet?

Does the media prefer ZBH or MMED?

Which has better earnings & valuation, ZBH or MMED?

Do analysts recommend ZBH or MMED?

Is ZBH or MMED more profitable?

Do institutionals and insiders hold more shares of ZBH or MMED?

Summary

How does MiniMed Group compare to Solventum?

Is SOLV or MMED more profitable?

Do institutionals & insiders believe in SOLV or MMED?

Which has higher valuation & earnings, SOLV or MMED?

Does the media favor SOLV or MMED?

Do analysts rate SOLV or MMED?

Summary

How does MiniMed Group compare to Smith & Nephew SNATS?

Do institutionals and insiders hold more shares of SNN or MMED?

Is SNN or MMED more profitable?

Do analysts recommend SNN or MMED?

Which has stronger earnings & valuation, SNN or MMED?

Does the media refer more to SNN or MMED?

Summary

How does MiniMed Group compare to Penumbra?

Do analysts recommend PEN or MMED?

Is PEN or MMED more profitable?

Which has better earnings and valuation, PEN or MMED?

Do insiders and institutionals have more ownership in PEN or MMED?

Does the media prefer PEN or MMED?

Summary

How does MiniMed Group compare to Glaukos?

Does the media favor MMED or GKOS?

Do institutionals and insiders believe in MMED or GKOS?

Do analysts prefer MMED or GKOS?

Is MMED or GKOS more profitable?

Which has higher earnings and valuation, MMED or GKOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MMED vs. The Competition

MiniMed Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools